Stock Track | Viking Therapeutics Soars 6.74% in Pre-market on Positive Phase 2b Results for NASH Drug VK2809

Stock Track11-20 17:02

Viking Therapeutics (NASDAQ: VKTX) witnessed a significant 6.74% surge in its stock price during the pre-market trading session on Wednesday. This rally can be attributed to the company's announcement of positive results from the Phase 2b clinical trial of its investigational drug VK2809 for the treatment of non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH).

The Phase 2b VOYAGE study met both its primary and secondary endpoints, demonstrating statistically significant reductions in liver fat content at Week 12 and Week 52. Patients receiving VK2809 showed mean relative reductions in liver fat ranging from 37% to 55% at Week 52, with 64% to 88% of patients achieving at least a 30% reduction.

Notably, the trial also reported impressive histologic results. Between 63% and 75% of VK2809-treated patients achieved resolution of NASH without worsening of fibrosis, compared to only 29% for the placebo group. Additionally, 44% to 57% of patients demonstrated improvement in fibrosis without worsening of NASH, versus 34% for placebo. These findings highlight VK2809's potential to address the underlying causes of NASH and associated liver damage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150702437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150702437","market":"us","top_or_hot":-1,"title":"Stock Track | Viking Therapeutics Soars 6.74% in Pre-market on Positive Phase 2b Results for NASH Drug VK2809","media":"Stock Track","content":"<p>Viking Therapeutics (NASDAQ: VKTX) witnessed a significant 6.74% surge in its stock price during the pre-market trading session on Wednesday. This rally can be attributed to the company's announcement of positive results from the Phase 2b clinical trial of its investigational drug VK2809 for the treatment of non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH).</p>\n\n<p>The Phase 2b VOYAGE study met both its primary and secondary endpoints, demonstrating statistically significant reductions in liver fat content at Week 12 and Week 52. Patients receiving VK2809 showed mean relative reductions in liver fat ranging from 37% to 55% at Week 52, with 64% to 88% of patients achieving at least a 30% reduction.</p>\n\n<p>Notably, the trial also reported impressive histologic results. Between 63% and 75% of VK2809-treated patients achieved resolution of NASH without worsening of fibrosis, compared to only 29% for the placebo group. Additionally, 44% to 57% of patients demonstrated improvement in fibrosis without worsening of NASH, versus 34% for placebo. These findings highlight VK2809's potential to address the underlying causes of NASH and associated liver damage.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viking Therapeutics Soars 6.74% in Pre-market on Positive Phase 2b Results for NASH Drug VK2809</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viking Therapeutics Soars 6.74% in Pre-market on Positive Phase 2b Results for NASH Drug VK2809\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-20 17:02 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viking Therapeutics (NASDAQ: VKTX) witnessed a significant 6.74% surge in its stock price during the pre-market trading session on Wednesday. This rally can be attributed to the company's announcement...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1150702437","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150702437","pubTimestamp":1732093351,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Viking Therapeutics  witnessed a significant 6.74% surge in its stock price during the pre-market trading session on Wednesday. This rally can be attributed to the company's announcement of positive results from the Phase 2b clinical trial of its investigational drug VK2809 for the treatment of non-alcoholic steatohepatitis  and metabolic dysfunction-associated steatohepatitis .The Phase 2b VOYAGE study met both its primary and secondary endpoints, demonstrating statistically significant reducti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"股票跟踪Viking Therapeutics因NASH药物VK2809的2b期结果积极而盘前飙升6.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1},"content_text":"Viking Therapeutics (NASDAQ: VKTX) witnessed a significant 6.74% surge in its stock price during the pre-market trading session on Wednesday. This rally can be attributed to the company's announcement of positive results from the Phase 2b clinical trial of its investigational drug VK2809 for the treatment of non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH).\nThe Phase 2b VOYAGE study met both its primary and secondary endpoints, demonstrating statistically significant reductions in liver fat content at Week 12 and Week 52. Patients receiving VK2809 showed mean relative reductions in liver fat ranging from 37% to 55% at Week 52, with 64% to 88% of patients achieving at least a 30% reduction.\nNotably, the trial also reported impressive histologic results. Between 63% and 75% of VK2809-treated patients achieved resolution of NASH without worsening of fibrosis, compared to only 29% for the placebo group. Additionally, 44% to 57% of patients demonstrated improvement in fibrosis without worsening of NASH, versus 34% for placebo. These findings highlight VK2809's potential to address the underlying causes of NASH and associated liver damage.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150702437"}